newsfilter
← Latest News
GlobeNewswire·

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today